TM6SF2 and metabolic dysfunction-associated steatotic liver disease: Furthermore, even if some of them (i.e. TM6SF2) have been reported to exert also an effect on cardiometabolic risk (both detrimental and protective), it is not known already their penetrance in the general population, apart from NAFLD patients.